Early research (Phase 1)Study completedNCT02101190What this trial is testingPharmacokinetics of BIA 9-1067 in Subjects With Hepatic ImpairmentWho this might be right forParkinson's Disease Bial - Portela C S.A. 16
Early research (Phase 1)Study completedNCT02080715What this trial is testingRole of the Catechol-O-methyltransferase (COMT) in the Physiological Regulation of VigilanceWho this might be right forHealthy University of Zurich 30
Not applicableUnknownNCT03845920What this trial is testingMod of Cognitive Flexibility by tDCS, Tyrosine Polymorphisms in the COMT GeneWho this might be right forModulation of Cognitive Flexibility by Transcranial Direct Current Stimulation, Tyrosine Administration and Polymorphisms in the COMT Gene Sheffield Hallam University 32
Not applicableTemporarily pausedNCT02179814What this trial is testingNeural Response to Catecholamine Depletion in Subjects Suffering From Bulimia Nervosa in Their Past and Healthy ControlsWho this might be right forBulimia NervosaEating DisordersDopamine+2 more University of Bern 60
Not applicableActive Not RecruitingNCT05043103What this trial is testingLong-Term Observational Study on Effectiveness and Safety of Lecigon in Patients With Advanced Parkinson's DiseaseWho this might be right forAdvanced Parkinson Disease Britannia Pharmaceuticals Ltd. 312
Not applicableUnknownNCT00773760What this trial is testingMOR and COMT SNP Polymorphism and PainWho this might be right forPain Relief East Tallinn Central Hospital 100
Not applicableUnknownNCT01075373What this trial is testingA Neurobiological Study on Heterogeneity of Schizophrenia: Genetic Variations and Neurobiological DifferentiationsWho this might be right forSchizophrenia National Taiwan University Hospital 360
Early research (Phase 1)Study completedNCT01520727What this trial is testingA Single Oral Ascending Dose Study of BIA 9-1067 in Healthy Male SubjectsWho this might be right forParkinson Disease Bial - Portela C S.A. 64
Testing effectiveness (Phase 2)Study completedNCT02634684What this trial is testingPharmacologically-augmented Cognitive Therapies (PACTs) for Schizophrenia.Who this might be right forSchizophrenia University of California, San Diego 82
Testing effectiveness (Phase 2)UnknownNCT03273062What this trial is testingA Trial Evaluating Effects of COMT Inhibition in Patients With Acquired Brain InjuryWho this might be right forBrain InjuriesBrain Injuries, TraumaticBrain Injury, Chronic Sheppard Pratt Health System 16
Very early researchStudy completedNCT00678730What this trial is testingPharmacogenetics of Cannabinoid ResponseWho this might be right forCOMT Gene Polymorphism Yale University 72
Not applicableUnknownNCT00664274What this trial is testingRelation of Catechol-O-methyltransferase (COMT) Genotype and Response to Cognitive Remediation SchizophreniaWho this might be right forChronic Schizophrenia Manhattan Psychiatric Center 142
Testing effectiveness (Phase 2)Study completedNCT01568034What this trial is testingInvestigate the Tolerability and Effect of Three Single-dose Regimens of BIA 9-1067Who this might be right forParkinson's Disease Bial - Portela C S.A. 10
Post-approval studies (Phase 4)Study completedNCT00373087What this trial is testingCOMT Polymorphism and Entacapone EfficacyWho this might be right forParkinson's Disease Assistance Publique - Hôpitaux de Paris 60
Testing effectiveness (Phase 2)Ended earlyNCT00548327What this trial is testingThe Effects of Atomoxetine on Cognition and Brain Function Based on Catechol-O-methyltransferase(COMT) GenotypeWho this might be right forSchizophreniaMemory DisordersCognition Disorders National Institute of Mental Health (NIMH) 11